{
    "id": 14535,
    "fullName": "TACSTD2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "TACSTD2 over exp indicates an over expression of the Tacstd2 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4070,
        "geneSymbol": "TACSTD2",
        "terms": [
            "TACSTD2",
            "EGP-1",
            "EGP1",
            "GA733-1",
            "GA7331",
            "GP50",
            "M1S1",
            "TROP2"
        ]
    },
    "variant": "over exp",
    "createDate": "11/28/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3687,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II clinical trial, Sacituzumab govitecan treatment resulted in 33% (2/6) partial response and 17% (1/6) stable disease in urothelial carcinoma patients over expressing Tacstd2 (PMID: 26541586).",
            "molecularProfile": {
                "id": 14781,
                "profileName": "TACSTD2 over exp"
            },
            "therapy": {
                "id": 3227,
                "therapyName": "Sacituzumab govitecan",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3993,
                    "pubMedId": 26541586,
                    "title": "Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26541586"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 14781,
            "profileName": "TACSTD2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}